Browse Studies — Arctuva

Phase 1

PRE-Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis: A Phase I/II Platform Trial

PRE-ISPY Phase I/II (I-SPY-P1) is an open-label, multisite platform study with multiple ongoing drug regimen arms added by protocol amendment which is designed…

HER2-positive Breast CancerMetastatic CancerMetastatic Breast Cancer+29 more

Estimated

~$10 – $7,500

QuantumLeap Healthcare CollaborativeNCT05868226

Phase 2

A Phase 2 Study Evaluating the Efficacy of Elacestrant in Patients With Estrogen Receptor Positive Uterine Sarcomas

This study is to evaluate the efficacy and safety of elacestrant, in participants with advanced estrogen receptor (ER)-positive uterine sarcomas. The name of t…

Uterine SarcomaUterine LeiomyosarcomaEndometrial Stromal Sarcoma+6 more

Estimated

~$10 – $7,500

Dana-Farber Cancer InstituteNCT07467772

Phase 2

I-CURE-1: A Phase II, Single Arm Study of Pembroluzimab Combined With Carboplatin in Patients With Circulating Tumor Cells (CTCs) Positive Her-2 Negative Metastatic Breast Cancer (MBC)

The purpose of the study is to evaluate the impact on progression-free survival (PFS) with the combination carboplatin - pembrolizumab in patients with CTC (ci…

Estrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu Negative+4 more

Estimated

~$10 – $6,250

Northwestern UniversityNCT03213041

Observational

Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive Breast Cancer

This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2…

Anatomic Stage IV Breast Cancer AJCC v8Estrogen Receptor PositiveHER2/Neu Negative+3 more

Estimated

~$10 – $7,500

SWOG Cancer Research NetworkNCT03723928